Baskent University
baskent.edu.trTotal trials
215
Active
36
Phase 3
7
Total enrollment
55,571
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 4 of 4 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Dexmedetomidine | — | — | — | — | — | 5 | |
| paracetamol | — | — | — | 4 | |||
| Lidocaine %2 ampoule | — | — | — | — | — | 1 | |
| conservative treatment | — | — | — | — | — | 1 |
Next readouts
- 2025-10
- 2025-12-31
Top conditions
- Nursing Education7
- Postoperative Pain6
- Obesity5
- Diabetes Mellitus, Type 25
- Hemodialysis4
- Stroke4
- Periodontitis4
- Anxiety3
Frequently asked questions about Baskent University
- How many clinical trials does Baskent University have on ClinicalTrials.gov?
- Baskent University is listed as the lead sponsor on 215 clinical trials in ClinicalTrials.gov, 36 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Baskent University's trials are in Phase 3?
- 7 of Baskent University's trials are in Phase 3, spread across 4 active drug programs.
- What therapeutic areas does Baskent University focus on?
- Baskent University's most-studied conditions on ClinicalTrials.gov are Nursing Education, Postoperative Pain, Obesity, Diabetes Mellitus, Type 2, Hemodialysis.
- When are Baskent University's next clinical trial readouts?
- Baskent University has 2 upcoming primary-completion readouts tracked here; the soonest is “Lidocaine, Paracetamol, and Dexmedetomidine for Rocuronium Injection Pain”, expected around 2025-10.